KLOW is a four-peptide research blend that has drawn growing interest in the peptide-research community, largely because it combines several of the most widely studied tissue-repair and anti-inflammatory compounds into a single formulation. This article provides an educational overview of what KLOW contains, how each component is studied, and its regulatory context in Australia. All information below is provided strictly for research and informational purposes.
What is in the KLOW blend?
KLOW is not a single molecule — it is a combination of four distinct research peptides supplied together as one lyophilised formulation. The standard KLOW composition, reflected in the 80mg total, brings together:
GHK-Cu (50mg) — a copper-binding tripeptide studied in skin, collagen and wound-healing research.
BPC-157 (10mg) — a synthetic pentadecapeptide widely studied in tissue-repair research.
TB-500 (10mg) — a synthetic fragment of thymosin beta-4 studied in cell-migration and recovery research.
KPV (10mg) — a tripeptide studied primarily for its anti-inflammatory signalling.
Because these are four separate compounds with four different primary mechanisms, KLOW is best understood not as a single active but as a research kit that assembles several distinct variables in one vial.
The four components and why they are studied
Each peptide in KLOW is examined through a different biological pathway in the research literature:
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine). Research literature examines it in the context of collagen and extracellular-matrix remodelling, fibroblast activity, and angiogenesis, which is why it appears frequently in skin and wound-healing research models.
BPC-157 is a synthetic pentadecapeptide derived from a protein sequence identified in gastric juice. Its research centres on angiogenesis — including its documented association with VEGFR2 expression — alongside collagen and fibroblast activity and nitric-oxide pathway modulation.
TB-500 is based on a segment of thymosin beta-4, a protein present in virtually all cells. The literature describes it as an actin-sequestering molecule, a mechanism central to cell movement, and it is predominantly studied through actin regulation and cell migration.
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (α-MSH). It is studied because it appears to retain the anti-inflammatory properties associated with α-MSH without the pigmentary activity of the parent hormone. Research literature describes it acting intracellularly, with reported modulation of NF-κB signalling and pro-inflammatory cytokine expression, and preclinical work has examined its uptake into intestinal epithelial cells via the PepT1 transporter in colitis models.
The common thread is that GHK-Cu, BPC-157 and TB-500 are each studied largely through tissue-repair and remodelling pathways, while KPV contributes a distinct anti-inflammatory research angle. This combination of different primary pathways is the reason the four are assembled together as a single research formulation.
How KLOW differs from the GLOW blend
KLOW is closely related to the GLOW blend, and the distinction is straightforward: GLOW combines three peptides — GHK-Cu, BPC-157 and TB-500 — while KLOW adds a fourth, KPV. In other words, KLOW can be understood as the GLOW composition with the anti-inflammatory tripeptide KPV included. Researchers comparing the two formulations are typically interested in what the addition of KPV's α-MSH-derived anti-inflammatory pathway contributes relative to the tissue-repair-focused profile of the three-peptide GLOW blend.
What the research has reported
The published research on all four KLOW components is predominantly preclinical — conducted in animal models and in-vitro systems — with human clinical data remaining limited across the board. It is worth stating explicitly that the research literature does not establish additive or synergistic effects between these compounds when combined. They are examined as separate research variables with distinct mechanisms, not as a single validated intervention. Researchers refer to current peer-reviewed publications for the most accurate and up-to-date findings on each individual compound.
Regulatory status in Australia
None of the KLOW components is approved by the Therapeutic Goods Administration (TGA), and none is listed on the Australian Register of Therapeutic Goods (ARTG). BPC-157 was additionally added to Schedule 4 (Prescription Only Medicine) under the Poisons Standard in 2024. KLOW and its individual components are supplied strictly as research compounds.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. KLOW and its component peptides are supplied strictly as research compounds, for in-vitro laboratory research use only. They are not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans, nor a recommendation to combine these compounds. Always refer to current published literature and applicable regulations, including the scheduling status of these compounds in your jurisdiction.